Regenerative Medicine Finally Feels The Love
Investment in regenerative medicine has boomed over the past couple years, according to data presented at the Alliance for Regenerative Medicine's third annual Regen Med Investor Day, and all signs point to an even bigger year in 2015.
You may also be interested in...
The Australian stem cell company said a Phase III trial being run by partner Teva and testing MPC-150-IM in chronic heart failure could finish earlier than expected because of an interim superiority analysis.
South Korea's Green Cross Holdings has invested in the clinical-stage U.S. biotech firm Juventas Therapeutics in a bid to diversify into the cell and gene therapy sector. Along with Posco Capital, Green Cross led a $7.5 million investment in the Cleveland-based company, which focuses on developing non-viral gene therapies to treat advanced cardiovascular diseases.
With big pharma on board, disappointments like the threatened EU market removal of pioneering Glybera and the Celladon trial failure give the field of gene therapy a bumpy ride after some major highs.